Gyno-Pevaryl (Econazole Nitrate)

Gyno-Pevaryl is indicated for the topical treatment of vaginal candidiasis caused by susceptible Candida species.

• Treatment of acute vaginal yeast infection confirmed by laboratory testing.
• Management of recurrent vulvovaginal candidiasis when prescribed by a healthcare professional.
• Adjunct therapy for mixed infections where a fungal component is identified.
• Use in patients who prefer a localized vaginal formulation over systemic antifungal agents.
• Prophylactic application in women undergoing antibiotic therapy that predisposes to yeast overgrowth, as advised by a clinician.
• Symptomatic relief of itching, burning, and discharge associated with Candida infection when used according to prescribed regimen.

The safety profile of Gyno-Pevaryl reflects the typical adverse events observed with intravaginal imidazole antifungals.

Common

• Mild vaginal irritation or burning sensation at the site of application.
• Localized itching or dryness.
• Unpleasant odor or discharge unrelated to infection.
• Transient spotting or light bleeding following application.
• Increased vaginal discharge that is thin and non‑purulent.
• Mild discomfort during intercourse while the medication is present.

Serious

• Severe allergic reaction such as rash, swelling, or difficulty breathing.
• Persistent or worsening vaginal symptoms despite therapy.
• Signs of secondary bacterial infection, including fever or foul-smelling discharge.
• Development of severe pelvic pain or abdominal cramps.
• Systemic symptoms such as headache, dizziness, or nausea that persist.
• Any reaction requiring immediate medical attention.

Before using Gyno-Pevaryl, certain precautions should be considered to ensure safe and effective treatment.

• Confirm diagnosis of vaginal candidiasis through appropriate clinical evaluation before initiating therapy.
• Avoid using the product if you have a known hypersensitivity to econazole nitrate or any imidazole antifungal.
• Do not insert the applicator beyond the recommended depth; follow the provided instructions carefully.
• Refrain from sexual intercourse, tampon use, or douching for at least 24 hours after application.
• If symptoms persist beyond the recommended treatment period, consult a healthcare professional.
• Pregnant or breastfeeding women should discuss potential risks with their provider before use.

Gyno-Pevaryl may interact with other substances applied vaginally or systemically; awareness of potential interactions helps maintain therapeutic effectiveness.

Avoid

• Concurrent use of other intravaginal antifungal or antiseptic products, which may reduce efficacy or increase irritation.
• Application of vaginal spermicides or lubricants containing non‑oil‑based formulations during treatment.

Use with caution

• Systemic azole antifungals (e.g., fluconazole) as combined therapy may increase risk of hepatic enzyme inhibition.
• Hormonal contraceptives administered vaginally, such as rings, should be monitored for possible reduced absorption.
• Use in patients with severe liver disease; although absorption is minimal, caution is advised.